Plasma levels of TNF-α and TNF-α production from lipopolysaccharide (LPS)-stimulated PBMC were evaluated in 26 CHF patients in comparison to controls. The effects of the A2AR agonist CGS-21680 and antagonist ZM-241385 on TNF-α production from PBMC were also evaluated. Finally, reverse transcriptase-polymerase chain reaction and Western blot analyses of A2AR in PBMC were performed in TNF-α–treated and untreated cells. TNF-α production from LPS-stimulated PBMC was enhanced in CHF patients with respect to controls. CGS-21680 blunted TNF-α production in both groups; ZM-241385 reverted this effect. A2AR expression in PBMC was higher in CHF patients than in controls. TNF-α addition produced an increase in A2AR in PBMC from controls but not in PBMC from CHF patients.
PBMC from CHF patients show an upregulation of A2AR-mediated inhibition of TNF-α, which may represents a mechanism of protection against inappropriate cytokine production.